Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Autores da FMUP
Participantes de fora da FMUP
- Sharma, A
- Caldeira, D
- Razaghizad, A
- Pinto, FJ
- van Veldhuisen, DJ
- Mehra, MR
- Lam, CSP
- Cleland, J
- Anker, SD
- Greenberg, B
- Zannad, F
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Sharma A,Caldeira D,Razaghizad A,Pinto FJ,van DJ,Mehra MR,Lam CSP,Cleland J,Anker SD,Greenberg B,Ferreira JP,Zannad F. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF. BMJ Open. 2023. 13. (8):p. 68865-68865. IF:2,900. (2).